Zinc / ROS Cancer Research Results

Z, Zinc: Click to Expand ⟱
Features:

Zinc (Zn²⁺) — essential trace element; structural/catalytic cofactor for >300 enzymes and ~10% of the human proteome (zinc-finger transcription factors). Obtained from diet/supplements (e.g., zinc gluconate, acetate, sulfate).

Primary mechanisms (conceptual rank):
1) Metalloprotein cofactor / transcriptional regulation (zinc-finger domains; p53 structural integrity)
2) Redox buffering & signaling modulation (indirect antioxidant; NADPH oxidase/SOD context)
3) Immune regulation (T-cell function; cytokine tone)
4) Apoptosis / mitochondrial signaling (dose-dependent)
5) Synaptic neuromodulation (brain Zn²⁺ pools; excitability)

Bioavailability / PK relevance: Tight homeostatic control (ZIP/ZnT transporters; metallothioneins). Oral absorption varies with form and dietary phytates; systemic free Zn²⁺ remains low (nanomolar). Many in-vitro cytotoxic effects use supra-physiologic micromolar levels.

In-vitro vs oral exposure: Direct tumor cytotoxicity typically at high concentrations (qualifier: high concentration only). Physiologic supplementation mainly corrects deficiency.

Clinical evidence status: Established for deficiency and immune support; oncology data mixed/observational; no stand-alone anti-cancer approval.

Zinc is an essential mineral that supports immune function, wound healing, skin health, and more.

Zinc is an essential cofactor for many enzymes, including superoxide dismutase (SOD), which scavenges free radicals and limits oxidative stress—a known contributor to DNA damage and cancer initiation.

Maintaining adequate zinc status (typically, serum concentrations within a normal reference range of roughly 70–120 µg/dL) is important for overall health, while both deficiency and excessive intake may have implications for cancer risk.

Some zinc-dependent enzymes, such as histone deacetylases (HDACs) or components of chromatin remodeling complexes, rely on zinc for their function.

Zinc can modulate several intracellular signaling cascades. For example, zinc ions may affect the activity of protein kinases and phosphatases.

Evidence suggests that alterations in zinc levels can impact growth factor signaling pathways, which are vital in controlling cell growth and survival and are often dysregulated in cancer.

Zinc is involved in the regulation of cell cycle progression and apoptosis (programmed cell death). It can modulate the activity of several transcription factors (e.g., p53) that regulate growth arrest and apoptosis in response to cellular stress.

Zinc (Zn²⁺) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 p53 structural integrity (zinc-finger stabilization) ↑ (if WT p53; context-dependent) R/G Tumor suppressor function support Zinc required for proper p53 conformation; deficiency impairs DNA damage response.
2 ROS ↓ (physiologic); ↑ (high concentration only) P/R Redox modulation Indirect antioxidant via metallothionein/SOD; excess Zn²⁺ can induce oxidative stress.
3 NRF2 axis ↑ (mild; context-dependent) R/G Stress-response activation Zinc can induce metallothionein and antioxidant gene expression.
4 Apoptosis (mitochondrial; caspases) ↑ or ↓ (dose-dependent) ↔ / ↑ (excess) R/G Cell death modulation Low physiologic levels protective; high intracellular Zn²⁺ may trigger apoptosis.
5 Immune signaling (NF-κB; cytokines) ↓ inflammatory tone (indirect) ↓ (balanced immune support) R/G Immune modulation Deficiency elevates inflammation; repletion normalizes cytokine signaling.
6 PI3K/AKT ↔ / ↑ (context-dependent) R/G Growth signaling influence Zinc transporters (ZIP4, ZIP6) implicated in tumor progression; effect is transporter-context specific.
7 HIF-1α ↓ (some models) G Hypoxia signaling modulation Reported inhibitory interaction in certain tumor models.
8 Ferroptosis ↔ (limited evidence) R/G Not primary axis Indirect influence via redox state possible but not canonical driver.
9 Ca²⁺ signaling ↔ / competitive modulation P/R Ion channel interaction Zinc can modulate NMDA and other channels; more relevant in neurons than oncology.
10 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) Tight homeostasis Systemic Zn²⁺ tightly regulated; excess supplementation may cause copper deficiency and immune imbalance.

TSF legend:
P: 0–30 min (ion-channel/redox interactions)
R: 30 min–3 hr (signaling modulation)
G: >3 hr (gene-regulatory/phenotype outcomes)


AD relevance: Zinc plays a dual role in Alzheimer’s disease: essential for synaptic function and antioxidant defense, but dysregulated Zn²⁺ can promote amyloid aggregation and excitotoxic injury.

Primary mechanisms (conceptual rank):
1) Aβ aggregation modulation (Zn²⁺ binding to amyloid)
2) Synaptic Zn²⁺ signaling (NMDA modulation; plasticity)
3) Redox buffering (metallothionein induction)
4) Neuroinflammation modulation
5) Tau phosphorylation influence (indirect)

Clinical evidence status: Mixed; deficiency harmful, excess potentially detrimental. No consensus that supplementation benefits established AD unless deficient.

Zinc (Zn²⁺) — AD / Neurodegeneration Pathway Map

Rank Pathway / Axis Cells TSF Primary Effect Notes / Interpretation
1 Aβ aggregation ↑ (excess); ↔ (physiologic) G Plaque stabilization potential Zinc binds Aβ; high synaptic Zn²⁺ may promote aggregation.
2 Synaptic transmission (NMDA modulation) ↔ / modulated P/R Plasticity regulation Vesicular Zn²⁺ co-released with glutamate; influences excitability.
3 ROS ↓ (physiologic); ↑ (excess) P/R Redox balance Deficiency increases oxidative stress; overload promotes injury.
4 NRF2 / Metallothionein ↑ (adaptive) R/G Antioxidant defense Metallothioneins buffer Zn²⁺ and reduce oxidative damage.
5 Neuroinflammation ↔ / ↓ (deficiency correction) R/G Immune balance Optimal zinc supports immune regulation; imbalance may exacerbate inflammation.
6 Ca²⁺ excitotoxicity interplay ↔ / ↑ (excess) P/R Excitotoxic vulnerability High Zn²⁺ can enter neurons and impair mitochondrial function.
7 Clinical Translation Constraint ↓ (constraint) Homeostatic narrow range Both deficiency and excess harmful; supplementation appropriate only if low.

TSF legend:
P: 0–30 min (synaptic ion effects)
R: 30 min–3 hr (signaling adaptation)
G: >3 hr (aggregation and phenotype changes)



ROS, Reactive Oxygen Species: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy
ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination

Item ROS NRF2 Condition Mechanism Class Remarks
ROS">Piperlongumine +++ [D][T] ROS-dominant
ROS">Shikonin +++↓/±[D][T]ROS-dominant
ROS">Vitamin K3 (menadione) +++[D]ROS-dominant
ROS">Copper (ionic / nano) +++[Fe][F]ROS-dominant
ROS">Sodium Selenite +++[D]ROS-dominant
ROS">Juglone +++[D]ROS-dominant
ROS">Auranofin +++[D]ROS-dominant
ROS">Photodynamic Therapy (PDT) +++0[L][O₂]ROS-dominant
ROS">Radiotherapy / Radiation +++0[O₂]ROS-dominant
ROS">Doxorubicin +++[D]ROS-dominant
ROS">Cisplatin ++[D][T]ROS-dominant
ROS">Salinomycin ++[D][T]ROS-dominant
ROS">Artemisinin / DHA ++[Fe][T]ROS-dominant
ROS">Sulfasalazine ++[C][T]ROS-dominant
ROS">FMD / fasting ++[M][C][O₂]ROS-dominant
ROS">Vitamin C (pharmacologic) ++[Fe][D]ROS-dominant
ROS">Silver nanoparticles ++±[F][D]ROS-dominant
ROS">Gambogic acid ++[D][T]ROS-dominant
ROS">Parthenolide ++[D][T]ROS-dominant
ROS">Plumbagin ++[D]ROS-dominant
ROS">Allicin ++[D]ROS-dominant
ROS">Ashwagandha (Withaferin A) ++[D][T]ROS-dominant
ROS">Berberine ++[D][M]ROS-dominant
ROS">PEITC ++[D][C]ROS-dominant
ROS">Methionine restriction +[M][C][T]ROS-secondary
ROS">DCA +±[M][T]ROS-secondary
ROS">Capsaicin +±[D][T]ROS-secondary
ROS">Galloflavin +0[D]ROS-secondary
ROS">Piperine +±[D][F]ROS-secondary
ROS">Propyl gallate +[D]ROS-secondary
ROS">Scoulerine +?[D][T]ROS-secondary
ROS">Thymoquinone ±±[D][T]Dual redox
ROS">Emodin ±±[D][T]Dual redox
ROS">Alpha-lipoic acid (ALA) ±[D][M]NRF2-dominant
ROS">Curcumin ±↑/↓[D][F]NRF2-dominant
ROS">EGCG ±↑/↓[D][O₂]NRF2-dominant
ROS">Quercetin ±↑/↓[D][Fe]NRF2-dominant
ROS">Resveratrol ±[D][M]NRF2-dominant
ROS">Sulforaphane ±↑↑[D]NRF2-dominant
ROS">Lycopene 0Antioxidant
ROS">Rosmarinic acid 0Antioxidant
ROS">Citrate 00Neutral


Scientific Papers found: Click to Expand⟱
2538- AgNPs,  SDT,  Z,    Dual-functional silver nanoparticle-enhanced ZnO nanorods for improved reactive oxygen species generation and cancer treatment
- Study, Var, NA - vitro+vivo, NA, NA
ROS↑, eff↑, eff↑, TumCP↓, toxicity↓,
1407- GoldNP,  Z,    The antioxidant effects of silver, gold, and zinc oxide nanoparticles on male mice in in vivo condition
- in-vivo, NA, NA
ROS↑, GPx↓, Catalase↓,
1221- Z,    Unexpected zinc dependency of ferroptosis: what is in a name?
- Analysis, Nor, NA
*Ferroptosis↑, *ROS↑, *lipid-P↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

Catalase↓, 1,   GPx↓, 1,   ROS↑, 2,  

Migration

TumCP↓, 1,  

Drug Metabolism & Resistance

eff↑, 2,  

Functional Outcomes

toxicity↓, 1,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

Ferroptosis↑, 1,   lipid-P↑, 1,   ROS↑, 1,  

Cell Death

Ferroptosis↑, 1,  
Total Targets: 4

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species
3 Zinc
1 Silver-NanoParticles
1 SonoDynamic Therapy UltraSound
1 Gold NanoParticles
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:170  Target#:275  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page